ENTPD1 and neoplasm: Given the role of the cricTMEM181–macrophage CD39–HCC CD73 axis in tumor growth and CD8+ T cells, we then explored whether interfering with this axis, especially CD39, can enhance the efficiency of PD1 immunotherapy.